Q3 2022 13F Holders as of 9/30/2022
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
99.6M
-
Number of holders
-
446
-
Total 13F shares, excl. options
-
90.2M
-
Shares change
-
-568K
-
Total reported value, excl. options
-
$9.58B
-
Value change
-
-$38M
-
Put/Call ratio
-
0.22
-
Number of buys
-
227
-
Number of sells
-
-202
-
Price
-
$106.21
Significant Holders of NEUROCRINE BIOSCIENCES INC - Common Stock (NBIX) as of Q3 2022
509 filings reported holding NBIX - NEUROCRINE BIOSCIENCES INC - Common Stock as of Q3 2022.
NEUROCRINE BIOSCIENCES INC - Common Stock (NBIX) has 446 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 90.2M shares
of 99.6M outstanding shares and own 90.53% of the company stock.
Largest 10 shareholders include BlackRock Inc. (12M shares), VANGUARD GROUP INC (9M shares), JANUS HENDERSON GROUP PLC (4.93M shares), STATE STREET CORP (3.77M shares), Bellevue Group AG (2.86M shares), JPMORGAN CHASE & CO (2.37M shares), Avidity Partners Management LP (1.86M shares), Bank of New York Mellon Corp (1.74M shares), DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) (1.51M shares), and PRICE T ROWE ASSOCIATES INC /MD/ (1.46M shares).
This table shows the top 446 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.